Sees FY23 revenue $14.8B-$15.4B, consensus $15.23B. Sees FY23 adjusted EBITDA $4.5B-$4.9B. Sees FY23 free cash flow $1.7B-$2.1B.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on TEVA:
- Israel’s TEVA, PERI Tank on Q4 Earnings; IZRL in Focus
- Evoke Pharma says joint stipulation of dismissal filed in GIMOTI case
- ANDA filing for generic Firdapse not a surprise, says Piper Sandler
- CPRX Plunges as Teva Targets Its Main LEMS Treatment
- Catalyst comments on the FDA’s position on orphan drug exclusivity